Details of the Drug

General Information of Drug (ID: DM9J04X)

Drug Name
Butalbital
Synonyms
Alisobumal; Alisobumalum; Allylbarbital; Allylbarbitone; Allylisobutylbarbital; Allylisobutylbarbiturate; Butalbarbital;Butalbitale; Butalbitalum; Itobarbital; Profundal; Sandoptal; Tetrallobarbital; Butalbitale [DCIT]; Axocet (TN); Axotal (TN); Bucet (TN); Bupap (TN); Butalbital [USAN:INN]; Butalbitalum [INN-Latin]; Cephadyn (TN); Dolgic (TN); Esgic (TN); Fioricet (TN); Fiorinal (TN); Fiormor (TN); Fiortal (TN); Fortabs (TN); IBS-L0126512; Iso-butylallylbarbituric acid; Laniroif (TN); Phrenilin (TN); Phrenilin Forte (TN); Sandoptal (TN); Sedapap (TN); Butalbital (USP/INN); Esgic-Plus (TN); 5-(2-methylpropyl)-5-(prop-2-en-1-yl)pyrimidine-2,4,6(1H,3H,5H)-trione; 5-(2-methylpropyl)-5-prop-2-en-1-ylpyrimidine-2,4,6(1H,3H,5H)-trione; 5-(2-methylpropyl)-5-prop-2-enyl-1,3-diazinane-2,4,6-trione; 5-Allyl-5-(2'-methyl-n-propyl) barbituric acid; 5-Allyl-5-(2-methylpropyl)barbituric acid; 5-Allyl-5-isobutyl-2,4,6(1H,3H,5H)-pyrimidinetrione; 5-Allyl-5-isobutyl-pyrimidine-2,4,6-trione; 5-Allyl-5-isobutylbarbituric acid
Indication
Disease Entry ICD 11 Status REF
Anxiety disorder 6B00-6B0Z Approved [1], [2], [3]
Headache 8A80-8A84 Approved [1], [2], [3]
Therapeutic Class
Analgesics
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 224.26
Topological Polar Surface Area (xlogp) 1.7
Rotatable Bond Count (rotbonds) 4
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 3
ADMET Property
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 2.1 mg/L [4]
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 2 h [4]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [5]
Bioavailability
85% of drug becomes completely available to its intended biological destination(s) [6]
Elimination
Butalbital predominantly undergoes renal elimination with 59 to 88% of the total dose administered being excreted from the kidneys as unchanged parent drug or metabolites [7]
Half-life
The concentration or amount of drug in body reduced by one-half in 35 hours [8]
Metabolism
The drug is metabolized via the hepatic [9]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 22.29537 micromolar/kg/day [10]
Vd
The volume of distribution (Vd) of drug is 0.8 L/kg [11]
Chemical Identifiers
Formula
C11H16N2O3
IUPAC Name
5-(2-methylpropyl)-5-prop-2-enyl-1,3-diazinane-2,4,6-trione
Canonical SMILES
CC(C)CC1(C(=O)NC(=O)NC1=O)CC=C
InChI
InChI=1S/C11H16N2O3/c1-4-5-11(6-7(2)3)8(14)12-10(16)13-9(11)15/h4,7H,1,5-6H2,2-3H3,(H2,12,13,14,15,16)
InChIKey
UZVHFVZFNXBMQJ-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
2481
ChEBI ID
CHEBI:102524
CAS Number
77-26-9
DrugBank ID
DB00241
TTD ID
D05BQK

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
GABA(A) receptor alpha-1 (GABRA1) TT1MPAY GBRA1_HUMAN Antagonist [12]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Butalbital
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Buspirone DMBS632 Moderate Increased metabolism of Butalbital caused by Buspirone mediated induction of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [17]
Coadministration of a Drug Treating the Disease Different from Butalbital (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Methylergonovine DMBEX4O Moderate Increased metabolism of Butalbital caused by Methylergonovine mediated induction of CYP450 enzyme. Abortion [JA00] [18]
Repaglinide DM5SXUV Moderate Increased metabolism of Butalbital caused by Repaglinide mediated induction of CYP450 enzyme. Acute diabete complication [5A2Y] [19]
Midostaurin DMI6E0R Moderate Increased metabolism of Butalbital caused by Midostaurin mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [20]
Gilteritinib DMWQ4MZ Moderate Increased metabolism of Butalbital caused by Gilteritinib mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [21]
Oliceridine DM6MDCF Major Additive CNS depression effects by the combination of Butalbital and Oliceridine. Acute pain [MG31] [22]
Mitotane DMU1GX0 Minor Increased metabolism of Butalbital caused by Mitotane mediated induction of CYP450 enzyme. Adrenal cancer [2D11] [23]
Donepezil DMIYG7Z Moderate Increased metabolism of Butalbital caused by Donepezil mediated induction of CYP450 enzyme. Alzheimer disease [8A20] [24]
Metronidazole DMTIVEN Moderate Increased metabolism of Butalbital caused by Metronidazole mediated induction of CYP450 enzyme. Amoebiasis [1A36] [25]
Ranolazine DM0C9IL Major Increased metabolism of Butalbital caused by Ranolazine mediated induction of CYP450 enzyme. Angina pectoris [BA40] [26]
Ivabradine DM0L594 Moderate Increased metabolism of Butalbital caused by Ivabradine mediated induction of CYP450 enzyme. Angina pectoris [BA40] [27]
Dronedarone DMA8FS5 Moderate Increased metabolism of Butalbital caused by Dronedarone mediated induction of CYP450 enzyme. Angina pectoris [BA40] [28]
Nifedipine DMSVOZT Moderate Increased metabolism of Butalbital caused by Nifedipine mediated induction of CYP450 enzyme. Angina pectoris [BA40] [29]
Bedaquiline DM3906J Moderate Increased metabolism of Butalbital caused by Bedaquiline mediated induction of CYP450 enzyme. Antimicrobial drug resistance [MG50-MG52] [30]
Voriconazole DMAOL2S Moderate Increased metabolism of Butalbital caused by Voriconazole mediated induction of CYP450 enzyme. Aspergillosis [1F20] [31]
Montelukast DMD157S Moderate Increased metabolism of Butalbital caused by Montelukast mediated induction of CYP450 enzyme. Asthma [CA23] [32]
Aminophylline DML2NIB Moderate Increased metabolism of Butalbital caused by Aminophylline mediated induction of CYP450 enzyme. Asthma [CA23] [33]
Tindamax DM3OWT4 Moderate Increased metabolism of Butalbital caused by Tindamax mediated induction of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [25]
Chloramphenicol DMFXEWT Moderate Increased metabolism of Butalbital caused by Chloramphenicol mediated induction of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [34]
Telithromycin DMZ4P3A Moderate Increased metabolism of Butalbital caused by Telithromycin mediated induction of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [35]
Cariprazine DMJYDVK Moderate Increased metabolism of Butalbital caused by Cariprazine mediated induction of CYP450 enzyme. Bipolar disorder [6A60] [27]
Ixabepilone DM2OZ3G Moderate Increased metabolism of Butalbital caused by Ixabepilone mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [36]
Lapatinib DM3BH1Y Moderate Increased metabolism of Butalbital caused by Lapatinib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [18]
LY2835219 DM93VBZ Moderate Increased metabolism of Butalbital caused by LY2835219 mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [37]
Exemestane DM9HPW3 Moderate Increased metabolism of Butalbital caused by Exemestane mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [38]
Esterified estrogens DM9KZDO Moderate Increased metabolism of Butalbital caused by Esterified estrogens mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [39]
Tucatinib DMBESUA Moderate Increased metabolism of Butalbital caused by Tucatinib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [35]
Palbociclib DMD7L94 Moderate Increased metabolism of Butalbital caused by Palbociclib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [18]
Alpelisib DMEXMYK Moderate Increased metabolism of Butalbital caused by Alpelisib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [40]
Quinestrol DMJ6H1Z Moderate Increased metabolism of Butalbital caused by Quinestrol mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [41]
Tamoxifen DMLB0EZ Moderate Increased metabolism of Butalbital caused by Tamoxifen mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [42]
Cabazitaxel DMPAZHC Moderate Increased metabolism of Butalbital caused by Cabazitaxel mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [43]
Toremifene DMQYUWG Moderate Increased metabolism of Butalbital caused by Toremifene mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [44]
Bosutinib DMTI8YE Moderate Increased metabolism of Butalbital caused by Bosutinib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [45]
Estradiol DMUNTE3 Moderate Increased metabolism of Butalbital caused by Estradiol mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [39]
Atorvastatin DMF28YC Moderate Increased metabolism of Butalbital caused by Atorvastatin mediated induction of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [46]
Macitentan DMP79A1 Moderate Increased metabolism of Butalbital caused by Macitentan mediated induction of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [47]
Doxercalciferol DM6FG1P Moderate Increased metabolism of Butalbital caused by Doxercalciferol mediated induction of CYP450 enzyme. Chronic kidney disease [GB61] [48]
Corticotropin DMP9TWZ Moderate Increased metabolism of Butalbital caused by Corticotropin mediated induction of CYP450 enzyme. Chronic kidney disease [GB61] [49]
PF-04449913 DMSB068 Moderate Increased metabolism of Butalbital caused by PF-04449913 mediated induction of CYP450 enzyme. Chronic myelomonocytic leukaemia [2A40] [50]
Dihydrocodeine DMB0FWL Major Additive CNS depression effects by the combination of Butalbital and Dihydrocodeine. Chronic pain [MG30] [51]
Morphine DMRMS0L Major Additive CNS depression effects by the combination of Butalbital and Morphine. Chronic pain [MG30] [52]
Anisindione DM2C48U Major Increased metabolism of Butalbital caused by Anisindione mediated induction of CYP450 enzyme. Coagulation defect [3B10] [53]
Irinotecan DMP6SC2 Moderate Increased metabolism of Butalbital caused by Irinotecan mediated induction of CYP450 enzyme. Colorectal cancer [2B91] [54]
Olopatadine DMKMWQG Moderate Additive CNS depression effects by the combination of Butalbital and Olopatadine. Conjunctiva disorder [9A60] [55]
Drospirenone DM1A9W3 Moderate Increased metabolism of Butalbital caused by Drospirenone mediated induction of CYP450 enzyme. Contraceptive management [QA21] [39]
Levonorgestrel DM1DP7T Moderate Increased metabolism of Butalbital caused by Levonorgestrel mediated induction of CYP450 enzyme. Contraceptive management [QA21] [39]
Ulipristal DMBNI20 Moderate Increased metabolism of Butalbital caused by Ulipristal mediated induction of CYP450 enzyme. Contraceptive management [QA21] [27]
Etonogestrel DMKA8J4 Moderate Increased metabolism of Butalbital caused by Etonogestrel mediated induction of CYP450 enzyme. Contraceptive management [QA21] [39]
Methoxyflurane DML0RAE Moderate Increased metabolism of Butalbital caused by Methoxyflurane mediated induction of CYP450 enzyme. Corneal disease [9A76-9A78] [56]
Lidocaine DML4ZOT Minor Increased metabolism of Butalbital caused by Lidocaine mediated induction of CYP450 enzyme. Corneal disease [9A76-9A78] [57]
Alfentanil DMVO0UB Major Additive CNS depression effects by the combination of Butalbital and Alfentanil. Corneal disease [9A76-9A78] [52]
Remifentanil DMZTXCH Major Additive CNS depression effects by the combination of Butalbital and Remifentanil. Corneal disease [9A76-9A78] [52]
Nimodipine DMQ0RKZ Moderate Increased metabolism of Butalbital caused by Nimodipine mediated induction of CYP450 enzyme. Coronary vasospastic disease [BA85] [29]
Oxtriphylline DMLHSE3 Moderate Increased metabolism of Butalbital caused by Oxtriphylline mediated induction of CYP450 enzyme. Cough [MD12] [33]
Methadone DMTW6IU Major Increased metabolism of Butalbital caused by Methadone mediated induction of CYP450 enzyme. Cough [MD12] [58]
Mifepristone DMGZQEF Moderate Increased metabolism of Butalbital caused by Mifepristone mediated induction of CYP450 enzyme. Cushing syndrome [5A70] [59]
Osilodrostat DMIJC9X Moderate Increased metabolism of Butalbital caused by Osilodrostat mediated induction of CYP450 enzyme. Cushing syndrome [5A70] [35]
Ivacaftor DMZC1HS Moderate Increased metabolism of Butalbital caused by Ivacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [60]
Ethanol DMDRQZU Major Additive CNS depression effects by the combination of Butalbital and Ethanol. Cystitis [GC00] [61]
Rivaroxaban DMQMBZ1 Moderate Increased metabolism of Butalbital caused by Rivaroxaban mediated induction of CYP450 enzyme. Deep vein thrombosis [BD71] [62]
Aprepitant DM053KT Moderate Increased metabolism of Butalbital caused by Aprepitant mediated induction of CYP450 enzyme. Depression [6A70-6A7Z] [63]
Fluoxetine DM3PD2C Minor Decreased metabolism of Butalbital caused by Fluoxetine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [64]
Vilazodone DM4LECQ Moderate Increased metabolism of Butalbital caused by Vilazodone mediated induction of CYP450 enzyme. Depression [6A70-6A7Z] [65]
Paroxetine DM5PVQE Minor Increased metabolism of Butalbital caused by Paroxetine mediated induction of CYP450 enzyme. Depression [6A70-6A7Z] [66]
Vortioxetine DM6F1PU Moderate Increased metabolism of Butalbital caused by Vortioxetine mediated induction of CYP450 enzyme. Depression [6A70-6A7Z] [67]
Esketamine DMVU687 Moderate Additive CNS depression effects by the combination of Butalbital and Esketamine. Depression [6A70-6A7Z] [18]
Griseofulvin DMK54YG Moderate Altered absorption of Butalbital caused by Griseofulvin. Dermatophytosis [1F28] [68]
[3H]estrone-3-sulphate DMGPF0N Moderate Increased metabolism of Butalbital caused by [3H]estrone-3-sulphate mediated induction of CYP450 enzyme. Discovery agent [N.A.] [41]
PMID28870136-Compound-48 DMPIM9L Moderate Increased metabolism of Butalbital caused by PMID28870136-Compound-48 mediated induction of CYP450 enzyme. Discovery agent [N.A.] [33]
Trihexyphenidyl DMB19L8 Moderate Additive CNS depression effects by the combination of Butalbital and Trihexyphenidyl. Dystonic disorder [8A02] [69]
Zonisamide DM0DTF7 Moderate Increased metabolism of Butalbital caused by Zonisamide mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [70]
Stiripentol DMMSDOY Moderate Increased metabolism of Butalbital caused by Stiripentol mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [27]
Phenytoin DMNOKBV Moderate Increased metabolism of Butalbital caused by Phenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [71]
Fosphenytoin DMOX3LB Moderate Increased metabolism of Butalbital caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [71]
Carbamazepine DMZOLBI Minor Increased metabolism of Butalbital caused by Carbamazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [72]
Timolol DM3NXRU Moderate Increased metabolism of Butalbital caused by Timolol mediated induction of CYP450 enzyme. Essential hypertension [BA00] [73]
Nicardipine DMCDYW7 Moderate Increased metabolism of Butalbital caused by Nicardipine mediated induction of CYP450 enzyme. Essential hypertension [BA00] [29]
Praziquantel DMOU1PK Moderate Increased metabolism of Butalbital caused by Praziquantel mediated induction of CYP450 enzyme. Flatworm infection [1F70-1F86] [74]
Bay 80-6946 DMLOS5R Moderate Increased metabolism of Butalbital caused by Bay 80-6946 mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [75]
Tazemetostat DMWP1BH Moderate Increased metabolism of Butalbital caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [76]
Solifenacin DMG592Q Moderate Increased metabolism of Butalbital caused by Solifenacin mediated induction of CYP450 enzyme. Functional bladder disorder [GC50] [77]
Mirabegron DMS1GYT Minor Increased metabolism of Butalbital caused by Mirabegron mediated induction of CYP450 enzyme. Functional bladder disorder [GC50] [78]
Darifenacin DMWXLYZ Moderate Increased metabolism of Butalbital caused by Darifenacin mediated induction of CYP450 enzyme. Functional bladder disorder [GC50] [79]
Caspofungin DMGQIPT Moderate Increased metabolism of Butalbital caused by Caspofungin mediated induction of CYP450 enzyme. Fungal infection [1F29-1F2F] [80]
Cimetidine DMH61ZB Minor Altered absorption of Butalbital caused by Cimetidine. Gastro-oesophageal reflux disease [DA22] [81]
Ripretinib DM958QB Moderate Increased metabolism of Butalbital caused by Ripretinib mediated induction of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [18]
Sunitinib DMCBJSR Moderate Increased metabolism of Butalbital caused by Sunitinib mediated induction of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [18]
Avapritinib DMK2GZX Moderate Increased metabolism of Butalbital caused by Avapritinib mediated induction of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [27]
Brimonidine DMQLT4N Moderate Additive CNS depression effects by the combination of Butalbital and Brimonidine. Glaucoma [9C61] [82]
Ergotamine DMKR3C5 Moderate Increased metabolism of Butalbital caused by Ergotamine mediated induction of CYP450 enzyme. Headache [8A80-8A84] [18]
Carvedilol DMHTEAO Moderate Increased metabolism of Butalbital caused by Carvedilol mediated induction of CYP450 enzyme. Heart failure [BD10-BD1Z] [73]
Digitoxin DMWVIGP Moderate Increased metabolism of Butalbital caused by Digitoxin mediated induction of CYP450 enzyme. Heart failure [BD10-BD1Z] [83]
Boceprevir DMBSHMF Moderate Increased metabolism of Butalbital caused by Boceprevir mediated induction of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [84]
Telaprevir DMMRV29 Moderate Increased metabolism of Butalbital caused by Telaprevir mediated induction of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [84]
MK-1439 DM215WE Moderate Increased metabolism of Butalbital caused by MK-1439 mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [85]
Delavirdine DM3NF5G Moderate Increased metabolism of Butalbital caused by Delavirdine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [86]
Fosamprenavir DM4W9B3 Moderate Increased metabolism of Butalbital caused by Fosamprenavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [87]
Fostemsavir DM50ILT Minor Increased metabolism of Butalbital caused by Fostemsavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [35]
Tipranavir DM8HJX6 Moderate Increased metabolism of Butalbital caused by Tipranavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [87]
Efavirenz DMC0GSJ Moderate Increased metabolism of Butalbital caused by Efavirenz mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [88]
Dolutegravir DMCZGRE Minor Increased metabolism of Butalbital caused by Dolutegravir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [89]
Saquinavir DMG814N Moderate Increased metabolism of Butalbital caused by Saquinavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [87]
Etravirine DMGV8QU Moderate Increased metabolism of Butalbital caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [90]
Rilpivirine DMJ0QOW Moderate Increased metabolism of Butalbital caused by Rilpivirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [18]
Amprenavir DMLMXE0 Moderate Increased metabolism of Butalbital caused by Amprenavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [91]
Darunavir DMN3GCH Moderate Increased metabolism of Butalbital caused by Darunavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [87]
Atazanavir DMSYRBX Moderate Increased metabolism of Butalbital caused by Atazanavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [87]
Maraviroc DMTL94F Moderate Increased metabolism of Butalbital caused by Maraviroc mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [18]
Ritonavir DMU764S Moderate Increased metabolism of Butalbital caused by Ritonavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [87]
Paricalcitol DMYBV3G Moderate Increased metabolism of Butalbital caused by Paricalcitol mediated induction of CYP450 enzyme. Hyper-parathyroidism [5A51] [48]
Acebutolol DM0TI4U Moderate Increased metabolism of Butalbital caused by Acebutolol mediated induction of CYP450 enzyme. Hypertension [BA00-BA04] [73]
Penbutolol DM4ES8F Moderate Increased metabolism of Butalbital caused by Penbutolol mediated induction of CYP450 enzyme. Hypertension [BA00-BA04] [92]
Losartan DM72JXH Minor Increased metabolism of Butalbital caused by Losartan mediated induction of CYP450 enzyme. Hypertension [BA00-BA04] [93]
Nebivolol DM7F1PA Moderate Increased metabolism of Butalbital caused by Nebivolol mediated induction of CYP450 enzyme. Hypertension [BA00-BA04] [73]
Nisoldipine DM7ISKJ Moderate Increased metabolism of Butalbital caused by Nisoldipine mediated induction of CYP450 enzyme. Hypertension [BA00-BA04] [29]
Levamlodipine DM92S6N Moderate Increased metabolism of Butalbital caused by Levamlodipine mediated induction of CYP450 enzyme. Hypertension [BA00-BA04] [29]
Isradipine DMA5XGH Moderate Increased metabolism of Butalbital caused by Isradipine mediated induction of CYP450 enzyme. Hypertension [BA00-BA04] [29]
Verapamil DMA7PEW Moderate Increased metabolism of Butalbital caused by Verapamil mediated induction of CYP450 enzyme. Hypertension [BA00-BA04] [94]
Diltiazem DMAI7ZV Moderate Increased metabolism of Butalbital caused by Diltiazem mediated induction of CYP450 enzyme. Hypertension [BA00-BA04] [95]
Amlodipine DMBDAZV Moderate Increased metabolism of Butalbital caused by Amlodipine mediated induction of CYP450 enzyme. Hypertension [BA00-BA04] [29]
Labetalol DMK8U72 Moderate Increased metabolism of Butalbital caused by Labetalol mediated induction of CYP450 enzyme. Hypertension [BA00-BA04] [73]
Metoprolol DMOJ0V6 Moderate Increased metabolism of Butalbital caused by Metoprolol mediated induction of CYP450 enzyme. Hypertension [BA00-BA04] [73]
Tolvaptan DMIWFRL Moderate Increased metabolism of Butalbital caused by Tolvaptan mediated induction of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [27]
Fludrocortisone DMUDIR8 Moderate Increased metabolism of Butalbital caused by Fludrocortisone mediated induction of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [49]
Levothyroxine DMHN027 Moderate Increased metabolism of Butalbital caused by Levothyroxine mediated induction of CYP450 enzyme. Hypo-thyroidism [5A00] [27]
Lesinurad DMUR64T Moderate Increased metabolism of Butalbital caused by Lesinurad mediated induction of CYP450 enzyme. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [96]
Suvorexant DM0E6S3 Moderate Increased metabolism of Butalbital caused by Suvorexant mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [97]
Eszopiclone DM8RZ9H Moderate Increased metabolism of Butalbital caused by Eszopiclone mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [98]
Tasimelteon DMLOQ1V Moderate Increased metabolism of Butalbital caused by Tasimelteon mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [99]
ITI-007 DMUQ1DO Major Increased metabolism of Butalbital caused by ITI-007 mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [100]
Naloxegol DML0B41 Moderate Increased metabolism of Butalbital caused by Naloxegol mediated induction of CYP450 enzyme. Large intestine motility disorder [DB32] [101]
Pemigatinib DM819JF Moderate Increased metabolism of Butalbital caused by Pemigatinib mediated induction of CYP450 enzyme. Liver cancer [2C12] [102]
Crizotinib DM4F29C Moderate Increased metabolism of Butalbital caused by Crizotinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [103]
Brigatinib DM7W94S Moderate Increased metabolism of Butalbital caused by Brigatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [18]
Ceritinib DMB920Z Moderate Increased metabolism of Butalbital caused by Ceritinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [104]
Erlotinib DMCMBHA Moderate Increased metabolism of Butalbital caused by Erlotinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [105]
Lurbinectedin DMEFRTZ Moderate Increased metabolism of Butalbital caused by Lurbinectedin mediated induction of CYP450 enzyme. Lung cancer [2C25] [106]
Osimertinib DMRJLAT Moderate Increased metabolism of Butalbital caused by Osimertinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [107]
Capmatinib DMYCXKL Moderate Increased metabolism of Butalbital caused by Capmatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [108]
Selpercatinib DMZR15V Moderate Increased metabolism of Butalbital caused by Selpercatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [35]
Artemether DM48QOT Moderate Increased metabolism of Butalbital caused by Artemether mediated induction of CYP450 enzyme. Malaria [1F40-1F45] [18]
Quinine DMSWYF5 Moderate Increased metabolism of Butalbital caused by Quinine mediated induction of CYP450 enzyme. Malaria [1F40-1F45] [109]
Mefloquine DMWT905 Moderate Increased metabolism of Butalbital caused by Mefloquine mediated induction of CYP450 enzyme. Malaria [1F40-1F45] [110]
Idelalisib DM602WT Moderate Increased metabolism of Butalbital caused by Idelalisib mediated induction of CYP450 enzyme. Mature B-cell leukaemia [2A82] [111]
GDC-0199 DMH0QKA Moderate Increased metabolism of Butalbital caused by GDC-0199 mediated induction of CYP450 enzyme. Mature B-cell leukaemia [2A82] [112]
Acalabrutinib DM7GCVW Moderate Increased metabolism of Butalbital caused by Acalabrutinib mediated induction of CYP450 enzyme. Mature B-cell lymphoma [2A85] [113]
Ibrutinib DMHZCPO Moderate Increased metabolism of Butalbital caused by Ibrutinib mediated induction of CYP450 enzyme. Mature B-cell lymphoma [2A85] [114]
Ponatinib DMYGJQO Moderate Increased metabolism of Butalbital caused by Ponatinib mediated induction of CYP450 enzyme. Mature B-cell lymphoma [2A85] [18]
Vemurafenib DM62UG5 Moderate Increased metabolism of Butalbital caused by Vemurafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [115]
Selumetinib DMC7W6R Moderate Increased metabolism of Butalbital caused by Selumetinib mediated induction of CYP450 enzyme. Melanoma [2C30] [116]
LGX818 DMNQXV8 Moderate Increased metabolism of Butalbital caused by LGX818 mediated induction of CYP450 enzyme. Melanoma [2C30] [117]
Estrone DM5T6US Moderate Increased metabolism of Butalbital caused by Estrone mediated induction of CYP450 enzyme. Menopausal disorder [GA30] [41]
Conjugated estrogens DMLT0E1 Moderate Increased metabolism of Butalbital caused by Conjugated estrogens mediated induction of CYP450 enzyme. Menopausal disorder [GA30] [39]
Ethinyl estradiol DMODJ40 Moderate Increased metabolism of Butalbital caused by Ethinyl estradiol mediated induction of CYP450 enzyme. Menopausal disorder [GA30] [41]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Butalbital and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [118]
Nitisinone DMVS9WQ Moderate Increased metabolism of Butalbital caused by Nitisinone mediated induction of CYP450 enzyme. Metabolism inborn error [5C50] [119]
Methysergide DM1EF73 Moderate Increased metabolism of Butalbital caused by Methysergide mediated induction of CYP450 enzyme. Migraine [8A80] [18]
Dihydroergotamine DM5IKUF Moderate Increased metabolism of Butalbital caused by Dihydroergotamine mediated induction of CYP450 enzyme. Migraine [8A80] [18]
Ubrogepant DM749I3 Moderate Increased metabolism of Butalbital caused by Ubrogepant mediated induction of CYP450 enzyme. Migraine [8A80] [120]
Propranolol DM79NTF Moderate Increased metabolism of Butalbital caused by Propranolol mediated induction of CYP450 enzyme. Migraine [8A80] [73]
Lasmiditan DMXLVDT Moderate Additive CNS depression effects by the combination of Butalbital and Lasmiditan. Migraine [8A80] [121]
Dihydrotachysterol DMFB97P Moderate Increased metabolism of Butalbital caused by Dihydrotachysterol mediated induction of CYP450 enzyme. Mineral deficiency [5B5K] [48]
Flibanserin DM70DTN Moderate Additive CNS depression effects by the combination of Butalbital and Flibanserin. Mood disorder [6A60-6E23] [122]
Panobinostat DM58WKG Moderate Increased metabolism of Butalbital caused by Panobinostat mediated induction of CYP450 enzyme. Multiple myeloma [2A83] [123]
Thalidomide DM70BU5 Moderate Additive CNS depression effects by the combination of Butalbital and Thalidomide. Multiple myeloma [2A83] [55]
Bexarotene DMOBIKY Minor Increased metabolism of Butalbital caused by Bexarotene mediated induction of CYP450 enzyme. Mycosis fungoides [2B01] [124]
Nilotinib DM7HXWT Moderate Increased metabolism of Butalbital caused by Nilotinib mediated induction of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [125]
Ruxolitinib DM7Q98D Moderate Increased metabolism of Butalbital caused by Ruxolitinib mediated induction of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [126]
Imatinib DM7RJXL Moderate Increased metabolism of Butalbital caused by Imatinib mediated induction of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [127]
Dasatinib DMJV2EK Moderate Increased metabolism of Butalbital caused by Dasatinib mediated induction of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [18]
Modafinil DMYILBE Moderate Increased metabolism of Butalbital caused by Modafinil mediated induction of CYP450 enzyme. Narcolepsy [7A20] [128]
Rolapitant DM8XP26 Moderate Increased metabolism of Butalbital caused by Rolapitant mediated induction of CYP450 enzyme. Nausea/vomiting [MD90] [129]
Bupropion DM5PCS7 Moderate Antagonize the effect of Butalbital when combined with Bupropion. Nicotine use disorder [6C4A] [130]
Entrectinib DMMPTLH Moderate Increased metabolism of Butalbital caused by Entrectinib mediated induction of CYP450 enzyme. Non-small cell lung cancer [2C25] [27]
Levomethadyl Acetate DM06HG5 Major Additive CNS depression effects by the combination of Butalbital and Levomethadyl Acetate. Opioid use disorder [6C43] [51]
Apraclonidine DMO4PVE Moderate Additive CNS depression effects by the combination of Butalbital and Apraclonidine. Optic nerve disorder [9C40] [82]
Olaparib DM8QB1D Moderate Increased metabolism of Butalbital caused by Olaparib mediated induction of CYP450 enzyme. Ovarian cancer [2C73] [18]
Altretamine DMKLAYG Moderate Increased metabolism of Butalbital caused by Altretamine mediated induction of CYP450 enzyme. Ovarian cancer [2C73] [131]
Pentazocine DM1XBHS Major Additive CNS depression effects by the combination of Butalbital and Pentazocine. Pain [MG30-MG3Z] [52]
Dextropropoxyphene DM23HCX Major Additive CNS depression effects by the combination of Butalbital and Dextropropoxyphene. Pain [MG30-MG3Z] [132]
Butorphanol DM5KYPJ Major Increased metabolism of Butalbital caused by Butorphanol mediated induction of CYP450 enzyme. Pain [MG30-MG3Z] [133]
Oxymorphone DM65AGJ Major Additive CNS depression effects by the combination of Butalbital and Oxymorphone. Pain [MG30-MG3Z] [52]
Levorphanol DMGS80V Major Additive CNS depression effects by the combination of Butalbital and Levorphanol. Pain [MG30-MG3Z] [52]
Hydromorphone DMHP21E Major Additive CNS depression effects by the combination of Butalbital and Hydromorphone. Pain [MG30-MG3Z] [52]
Dezocine DMJDB0Y Major Additive CNS depression effects by the combination of Butalbital and Dezocine. Pain [MG30-MG3Z] [51]
Codeine DMJX6ZG Major Additive CNS depression effects by the combination of Butalbital and Codeine. Pain [MG30-MG3Z] [52]
Nalbuphine DMOSQGU Major Additive CNS depression effects by the combination of Butalbital and Nalbuphine. Pain [MG30-MG3Z] [52]
Buprenorphine DMPRI8G Major Additive CNS depression effects by the combination of Butalbital and Buprenorphine. Pain [MG30-MG3Z] [134]
Hydrocodone DMQ2JO5 Major Increased metabolism of Butalbital caused by Hydrocodone mediated induction of CYP450 enzyme. Pain [MG30-MG3Z] [58]
Acetaminophen DMUIE76 Moderate Increased metabolism of Butalbital caused by Acetaminophen mediated induction of CYP450 enzyme. Pain [MG30-MG3Z] [135]
Meperidine DMX4GND Major Increased metabolism of Butalbital caused by Meperidine mediated induction of CYP450 enzyme. Pain [MG30-MG3Z] [27]
Biperiden DME78OA Moderate Additive CNS depression effects by the combination of Butalbital and Biperiden. Parkinsonism [8A00] [69]
Benztropine DMGZOVN Moderate Additive CNS depression effects by the combination of Butalbital and Benztropine. Parkinsonism [8A00] [69]
Procyclidine DMHFJDT Moderate Additive CNS depression effects by the combination of Butalbital and Procyclidine. Parkinsonism [8A00] [69]
Pimavanserin DMR7IVC Moderate Increased metabolism of Butalbital caused by Pimavanserin mediated induction of CYP450 enzyme. Parkinsonism [8A00] [136]
Doxycycline DM7ICNU Moderate Increased metabolism of Butalbital caused by Doxycycline mediated induction of CYP450 enzyme. Periodontal disease [DA0C] [137]
Macimorelin DMQYJIR Moderate Increased metabolism of Butalbital caused by Macimorelin mediated induction of CYP450 enzyme. Pituitary gland disorder [5A60-5A61] [138]
Dapsone DM4LT8A Minor Increased metabolism of Butalbital caused by Dapsone mediated induction of CYP450 enzyme. Pneumonia [CA40] [139]
Lefamulin DME6G97 Moderate Increased metabolism of Butalbital caused by Lefamulin mediated induction of CYP450 enzyme. Pneumonia [CA40] [140]
Prednisone DM2HG4X Moderate Increased metabolism of Butalbital caused by Prednisone mediated induction of CYP450 enzyme. Postoperative inflammation [1A00-CA43] [49]
Betamethasone DMAHJEF Moderate Increased metabolism of Butalbital caused by Betamethasone mediated induction of CYP450 enzyme. Postoperative inflammation [1A00-CA43] [49]
Hydrocortisone DMGEMB7 Moderate Increased metabolism of Butalbital caused by Hydrocortisone mediated induction of CYP450 enzyme. Postoperative inflammation [1A00-CA43] [49]
Ergonovine DM0VEC1 Moderate Increased metabolism of Butalbital caused by Ergonovine mediated induction of CYP450 enzyme. Postpartum haemorrhage [JA43] [18]
Lonafarnib DMGM2Z6 Moderate Increased metabolism of Butalbital caused by Lonafarnib mediated induction of CYP450 enzyme. Premature ageing appearance [LD2B] [141]
Progesterone DMUY35B Moderate Increased metabolism of Butalbital caused by Progesterone mediated induction of CYP450 enzyme. Preterm labour/delivery [JB00] [39]
Enzalutamide DMGL19D Moderate Increased metabolism of Butalbital caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [142]
Darolutamide DMV7YFT Moderate Increased metabolism of Butalbital caused by Darolutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [143]
Apremilast DMTWS9E Moderate Increased metabolism of Butalbital caused by Apremilast mediated induction of CYP450 enzyme. Psoriasis [EA90] [144]
Riociguat DMXBLMP Moderate Increased metabolism of Butalbital caused by Riociguat mediated induction of CYP450 enzyme. Pulmonary hypertension [BB01] [145]
Everolimus DM8X2EH Moderate Increased metabolism of Butalbital caused by Everolimus mediated induction of CYP450 enzyme. Renal cell carcinoma [2C90] [18]
Axitinib DMGVH6N Moderate Increased metabolism of Butalbital caused by Axitinib mediated induction of CYP450 enzyme. Renal cell carcinoma [2C90] [146]
Temsirolimus DMS104F Moderate Increased metabolism of Butalbital caused by Temsirolimus mediated induction of CYP450 enzyme. Renal cell carcinoma [2C90] [18]
Tofacitinib DMBS370 Moderate Increased metabolism of Butalbital caused by Tofacitinib mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [18]
Fenoprofen DML5VQ0 Minor Increased metabolism of Butalbital caused by Fenoprofen mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [147]
Dexamethasone DMMWZET Moderate Increased metabolism of Butalbital caused by Dexamethasone mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [49]
Quetiapine DM1N62C Moderate Increased metabolism of Butalbital caused by Quetiapine mediated induction of CYP450 enzyme. Schizophrenia [6A20] [18]
Aripiprazole DM3NUMH Moderate Increased metabolism of Butalbital caused by Aripiprazole mediated induction of CYP450 enzyme. Schizophrenia [6A20] [148]
Fentanyl DM8WAHT Major Increased metabolism of Butalbital caused by Fentanyl mediated induction of CYP450 enzyme. Sensation disturbance [MB40] [133]
Sufentanil DMU7YEL Major Additive CNS depression effects by the combination of Butalbital and Sufentanil. Sensation disturbance [MB40] [52]
Avanafil DM75CXN Moderate Increased metabolism of Butalbital caused by Avanafil mediated induction of CYP450 enzyme. Sexual dysfunction [HA00-HA01] [149]
Tadalafil DMJZHT1 Moderate Increased metabolism of Butalbital caused by Tadalafil mediated induction of CYP450 enzyme. Sexual dysfunction [HA00-HA01] [27]
LDE225 DMM9F25 Moderate Increased metabolism of Butalbital caused by LDE225 mediated induction of CYP450 enzyme. Skin cancer [2C30-2C37] [150]
Gefitinib DM15F0X Moderate Increased metabolism of Butalbital caused by Gefitinib mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [105]
Larotrectinib DM26CQR Moderate Increased metabolism of Butalbital caused by Larotrectinib mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [18]
Methylprednisolone DM4BDON Moderate Increased metabolism of Butalbital caused by Methylprednisolone mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [49]
Docetaxel DMDI269 Moderate Increased metabolism of Butalbital caused by Docetaxel mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [151]
Trabectedin DMG3Y89 Moderate Increased metabolism of Butalbital caused by Trabectedin mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [27]
Armodafinil DMGB035 Moderate Increased metabolism of Butalbital caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [128]
LEE011 DMMX75K Moderate Increased metabolism of Butalbital caused by LEE011 mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [18]
Prednisolone DMQ8FR2 Moderate Increased metabolism of Butalbital caused by Prednisolone mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [49]
Norethindrone DMTY169 Moderate Increased metabolism of Butalbital caused by Norethindrone mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [41]
Taxol DMUOT9V Moderate Increased metabolism of Butalbital caused by Taxol mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [152]
Doxorubicin DMVP5YE Moderate Increased metabolism of Butalbital caused by Doxorubicin mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [27]
Warfarin DMJYCVW Major Increased metabolism of Butalbital caused by Warfarin mediated induction of CYP450 enzyme. Supraventricular tachyarrhythmia [BC81] [153]
Fostamatinib DM6AUHV Moderate Increased metabolism of Butalbital caused by Fostamatinib mediated induction of CYP450 enzyme. Thrombocytopenia [3B64] [35]
Apixaban DM89JLN Moderate Increased metabolism of Butalbital caused by Apixaban mediated induction of CYP450 enzyme. Thrombosis [DB61-GB90] [154]
Brilinta DMBR01X Moderate Increased metabolism of Butalbital caused by Brilinta mediated induction of CYP450 enzyme. Thrombosis [DB61-GB90] [119]
Dicumarol DMFQCB1 Major Increased metabolism of Butalbital caused by Dicumarol mediated induction of CYP450 enzyme. Thrombosis [DB61-GB90] [53]
Tizanidine DMR2IQ4 Moderate Additive CNS depression effects by the combination of Butalbital and Tizanidine. Tonus and reflex abnormality [MB47] [155]
Sirolimus DMGW1ID Moderate Increased metabolism of Butalbital caused by Sirolimus mediated induction of CYP450 enzyme. Transplant rejection [NE84] [18]
Tacrolimus DMZ7XNQ Moderate Increased metabolism of Butalbital caused by Tacrolimus mediated induction of CYP450 enzyme. Transplant rejection [NE84] [18]
Canagliflozin DMFRM1I Moderate Increased metabolism of Butalbital caused by Canagliflozin mediated induction of UGT. Type 2 diabetes mellitus [5A11] [18]
Saxagliptin DMGXENV Moderate Increased metabolism of Butalbital caused by Saxagliptin mediated induction of CYP450 enzyme. Type 2 diabetes mellitus [5A11] [156]
Linagliptin DMWFJTR Moderate Increased metabolism of Butalbital caused by Linagliptin mediated induction of CYP450 enzyme. Type 2 diabetes mellitus [5A11] [157]
Elagolix DMB2C0E Moderate Increased metabolism of Butalbital caused by Elagolix mediated induction of CYP450 enzyme. Uterine fibroid [2E86] [158]
Triamcinolone DM98IXF Moderate Increased metabolism of Butalbital caused by Triamcinolone mediated induction of CYP450 enzyme. Vasomotor/allergic rhinitis [CA08] [49]
Cetirizine DMOMP9U Moderate Additive CNS depression effects by the combination of Butalbital and Cetirizine. Vasomotor/allergic rhinitis [CA08] [159]
Disopyramide DM5SYZP Moderate Increased metabolism of Butalbital caused by Disopyramide mediated induction of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [160]
Propafenone DMPIBJK Minor Increased metabolism of Butalbital caused by Propafenone. Ventricular tachyarrhythmia [BC71] [161]
⏷ Show the Full List of 249 DDI Information of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7138).
2 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 076528.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
5 BDDCS applied to over 900 drugs
6 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
7 Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules - FDA Label
8 Blood and plasma concentrations of butalbital following single oral doses in man. J Anal Toxicol. 1988 Nov-Dec;12(6):322-4.
9 Povirk LF, Shuker DE: DNA damage and mutagenesis induced by nitrogen mustards. Mutat Res. 1994 Dec;318(3):205-26. doi: 10.1016/0165-1110(94)90015-9.
10 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
11 An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
12 DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
13 Zolpidem, a selective GABA(A) receptor alpha1 subunit agonist, induces comparable Fos expression in oxytocinergic neurons of the hypothalamic paraventricular and accessory but not supraoptic nuclei in the rat.Brain Res Bull.2006 Dec 11;71(1-3):200-7.
14 Neurosteroid analogues. 10. The effect of methyl group substitution at the C-6 and C-7 positions on the GABA modulatory and anesthetic actions of (... J Med Chem. 2005 Apr 21;48(8):3051-9.
15 3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7.
16 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
17 Kivisto KT, Lamberg TS, Neuvonen PJ "Interactions of buspirone with itraconazole and rifampicin: Effects on the pharmacokinetics of the active 1-(2-pyrimidinyl)-piperazine metabolite of buspirone." Pharmacol Toxicol 84 (1999): 94-7. [PMID: 10068153]
18 Cerner Multum, Inc. "Australian Product Information.".
19 Bidstrup TB, Bjornsdottir I, Sidelmann UG, Thomsen MS, Hansen KT "CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide." Br J Clin Pharmacol 56 (2003): 305-14. [PMID: 12919179]
20 Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y "Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers." Cancer Chemother Pharmacol 72 (2013): 1223-34. [PMID: 24085261]
21 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
22 Liu S-J, Wang RI "Case report of barbiturate-induced enhancement of methadone metabolism and withdrawal syndrome." Am J Psychiatry 141 (1984): 1287-8. [PMID: 6486271]
23 Product Information. Lysodren (mitotane). Bristol-Myers Squibb, Princeton, NJ.
24 Product Information. Aricept (donepezil). Pfizer US Pharmaceuticals, New York, NY.
25 Gupte S "Phenobarbital and metabolism of metronidazole." N Engl J Med 308 (1983): 529. [PMID: 6823276]
26 Product Information. Ranexa (ranolazine). Calmoseptine Inc, Huntington Beach, CA.
27 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
28 Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
29 Hamann SR, Blouin RA, Chang SL, et al "Effects of hemodynamic changes on the elimination kinetics of verapamil and nifedipine." J Pharmacol Exp Ther 231 (1984): 301-5. [PMID: 6491984]
30 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
31 Product Information. VFEND (voriconazole). Pfizer U.S. Pharmaceuticals, New York, NY.
32 Product Information. Singulair (montelukast). Merck & Co, Inc, West Point, PA.
33 Bukowskyj M, Nakatsu K, Munt PW "Theophylline reassessed." Ann Intern Med 101 (1984): 63-73. [PMID: 6145380]
34 Ambrose PJ "Clinical pharmacokinetics of chloramphenicol and chloramphenicol succinate." Clin Pharmacokinet 9 (1984): 222-38. [PMID: 6375931]
35 Product Information. Diabinese (chlorpropamide). Pfizer US Pharmaceuticals, New York, NY.
36 Product Information. Ixempra (ixabepilone). Bristol-Myers Squibb, Princeton, NJ.
37 Product Information. Verzenio (abemaciclib). Lilly, Eli and Company, Indianapolis, IN.
38 Product Information. Aromasin (exemestane) Pharmacia & Upjohn, Kalamazoo, MI.
39 Baciewicz AM "Oral contraceptive drug interactions." Ther Drug Monit 7 (1985): 26-35. [PMID: 2859674]
40 Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
41 Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH "Interindividual variation and drug interactions with hormonal steroid contraceptives." Drugs 21 (1981): 46-61. [PMID: 7009137]
42 Biochem Pharmacol "Variable contribution of cytochromes P450 2D6, 2C9, and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes." Biochem Pharmacol 53 (1997): 171-8. [PMID: 9037249]
43 Product Information. Jevtana (cabazitaxel). sanofi-aventis , Bridgewater, NJ.
44 Berthou F, Dreano Y, Belloc C, Kangas L, Gautier JC, Beaune P "Involvement of cytochrome P450 3A enzyme family in the major metabolic pathways of toremifene in human liver microsomes." Biochem Pharmacol 47 (1994): 1883-95. [PMID: 8204106]
45 Product Information. Bosulif (bosutinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
46 Bullman J, Nicholls A, Van Landingham K, et al. "Effects of lamotrigine and phenytoin on the pharmacokinetics of atorvastatin in healthy volunteers." Epilepsia 52 (2011): 1351-8. [PMID: 21635243]
47 Bruderer S, Aanismaa P, Homery MC, et al. "Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist." AAPS J 14 (2012): 68-78. [PMID: 22189899]
48 Product Information. Hectorol (doxercalciferol). Genzyme Corporation, Cambridge, MA.
49 Bartoszek M, Brenner AM, Szefler SJ "Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy." Clin Pharmacol Ther 42 (1987): 424-32. [PMID: 3665340]
50 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
51 US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
52 US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
53 Antlitz AM, Tolentino M, Kosai MF "Effect of butabarbital on orally administered anticoagulants." Curr Ther Res Clin Exp 10 (1968): 70-3. [PMID: 4967727]
54 Crews KR, Stewart CF, Jones-Wallace D, et al "Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy." Clin Cancer Res 8 (2002): 2202-9. [PMID: 12114421]
55 Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
56 Brodeur J, Paquin P, Authier L, Geadah D, Yamauchi M, Cote MG "Influence of phenobarbital pretreatment on methoxyflurane and sodium fluoride nephropathy in Fischer 344 Rats." Toxicol Appl Pharmacol 37 (1976): 349-61. [PMID: 982456]
57 Heinonen J, Takki S, Jarho L "Plasma lidocaine levels in patients treated with potential inducers of microsomal enzymes." Acta Anaesthesiol Scand 14 (1970): 89-95. [PMID: 5428253]
58 Bell J, Seres V, Bowron P, Lewis J, Batey R "The use of serum methadone levels in patients receiving methadone maintenance." Clin Pharmacol Ther 43 (1988): 623-9. [PMID: 3378383]
59 Product Information. Korlym (mifepristone). Corcept Therapeutics Incorporated, Menlo Park, CA.
60 Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
61 Gupta RC, Kofoed J "Toxological statistics for barbiturates, other sedatives, and tranquilizers in Ontario: a 10-year survey." Can Med Assoc J 94 (1966): 863-5. [PMID: 5929537]
62 Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
63 Product Information. Emend (aprepitant). Merck & Company Inc, West Point, PA.
64 Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions. II." J Clin Psychopharmacol 10 (1990): 213-7. [PMID: 2198298]
65 Product Information. Viibryd (vilazodone). Trovis Pharmaceuticals LLC, New Haven, CT.
66 Product Information. Paxil (paroxetine). GlaxoSmithKline, Research Triangle Park, NC.
67 Product Information. Brintellix (vortioxetine). Takeda Pharmaceuticals America, Lincolnshire, IL.
68 Busfield D, Child KJ, Atkinson RM, Tomich EG "An effect of phenobarbitone on blood-levels of griseofulvin in man." Lancet 2 (1963): 1042-3. [PMID: 14062729]
69 Product Information. Artane (trihexyphenidyl). Lederle Laboratories, Wayne, NJ.
70 Nakasa H, Nakamura H, Ono S, Tsutsui M, Kiuchi M, Ohmori S, Kitada M "Prediction of drug-drug interactions of zonisamide metabolism in humans from in vitro data." Eur J Clin Pharmacol 54 (1998): 177-83. [PMID: 9626925]
71 Kuranari M, Tatsukawa H, Seike M, et al. "Effect of phenytoin on phenobarbital pharmacokinetics in a patient with epilepsy." Ann Pharmacother 29 (1995): 83-4. [PMID: 7711354]
72 Benetello P, Furlanut M "Primidone-carbamazepine interaction: clinical consequences." Int J Clin Pharmacol Res 7 (1987): 165-8. [PMID: 3583497]
73 Branch RA, Herman RJ "Enzyme induction and beta-adrenergic receptor blocking drugs." Br J Clin Pharmacol 17 (1984): s77-84. [PMID: 6146342]
74 Bittencourt PR, Gracia CM, Martins R, et al "Phenytoin and carbamazepine decrease oral bioavailability of praziquantel." Neurology 42 (1992): 492-6. [PMID: 1549207]
75 Product Information. Aliqopa (copanlisib). Bayer Pharmaceutical Inc, West Haven, CT.
76 Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
77 Product Information. VESIcare (solifenacin). GlaxoSmithKline, Research Triangle Park, NC.
78 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
79 Product Information. Enablex (darifenacin). Novartis Pharmaceuticals, East Hanover, NJ.
80 Product Information. Cancidas (caspofungin) Merck & Co, Inc, West Point, PA.
81 Somogyi A, Thielscher S, Gugler R "Influence of phenobarbital treatment on cimetidine kinetics." Eur J Clin Pharmacol 19 (1981): 343-7. [PMID: 7238562]
82 Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
83 Cardoso MT, Carvalhas ML. Effects of phenobarbital on digitoxin metabolism in guinea-pig liver slices. Xenobiotica. 1980;10(10):779-784. [PMID: 7456493]
84 Product Information. Incivek (telaprevir). Vertex Pharmaceuticals, Cambridge, MA.
85 Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
86 Borin MT, Chambers JH, Carel BJ, Gagnon S, Freimuth WW "Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate." Clin Pharmacol Ther 61 (1997): 544-53. [PMID: 9164416]
87 Acosta EP, Henry K, Baken L, Page LM, Fletcher CV "Indinavir concentrations and antiviral effect." Pharmacotherapy 19 (1999): 708-12. [PMID: 10391416]
88 Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T "Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients." Aids 15 (2001): 71-5. [PMID: 11192870]
89 Product Information. Tivicay (dolutegravir). ViiV Healthcare, Research Triangle Park, NC.
90 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
91 Product Information. Reyataz (atazanavir). Bristol-Myers Squibb, Princeton, NJ.
92 Haglund K, Seideman P, Colliste P, Borg KO, von Bahr C "Influence of pentobarbital on metoprolol plasma levels." Clin Pharmacol Ther 26 (1979): 326-9. [PMID: 466926]
93 Goldberg MR, Lo MW, Deutsch PJ, Wilson SE, Mcwilliams EJ, Mccrea JB "Phenobarbital minimally alters plasma concentrations of losartan and its active metabolite e-3174." Clin Pharmacol Ther 59 (1996): 268-74. [PMID: 8653989]
94 Rutledge DR, Pieper JA, Mirvis DM "Effects of chronic phenobarbital on verapamil dispostion in humans." J Pharmacol Exp Ther 246 (1988): 7-13. [PMID: 3392664]
95 Borcherding SM, Baciewicz AM, Self TH "Update on rifampin drug interactions." Arch Intern Med 152 (1992): 711-6. [PMID: 1558427]
96 Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John's Wort." Am J Med 112 (2002): 507-8. [PMID: 11959071]
97 Product Information. Belsomra (suvorexant). Merck & Company Inc, Whitehouse Station, NJ.
98 Product Information. Lunesta (eszopiclone). Sepracor Inc, Marlborough, MA.
99 Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
100 Product Information. Caplyta (lumateperone). Intra-Cellular Therapies, Inc., New York, NY.
101 Product Information. Movantik (naloxegol). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
102 Product Information. Pemazyre (pemigatinib). Incyte Corporation, Wilmington, DE.
103 Cerner Multum, Inc. "Canadian Product Information.".
104 Product Information. Zykadia (ceritinib). Novartis Pharmaceuticals, East Hanover, NJ.
105 Li J, Zhao M, He P, Hidalgo M, Baker SD "Differential metabolism of gefitinib and erlotinib by human cytochrome p450 enzymes." Clin Cancer Res 13 (2007): 3731-7. [PMID: 17575239]
106 Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
107 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
108 Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
109 Fabre C, Criddle J, Nolder D, Klein JL "Recrudescence of imported falciparum malaria after quinine therapy: potential drug interaction with phenytoin." Trans R Soc Trop Med Hyg 99 (2005): 871-3. [PMID: 16099004]
110 Product Information. Lariam (mefloquine). Roche Laboratories, Nutley, NJ.
111 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
112 Product Information. Venclexta (venetoclax). AbbVie US LLC, North Chicago, IL.
113 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
114 Product Information. Imbruvica (ibrutinib). Pharmacyclics Inc, Sunnyvale, CA.
115 Product Information. Zelboraf (vemurafenib). Genentech, South San Francisco, CA.
116 Product Information. Koselugo (selumetinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
117 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
118 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
119 Canadian Pharmacists Association.
120 Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
121 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
122 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
123 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
124 Product Information. Targretin (bexarotene) Ligand Pharmaceuticals, San Diego, CA.
125 Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
126 Product Information. Jakafi (ruxolitinib). Incyte Corporation, Wilmington, DE.
127 Bolton AE, Peng B, Hubert M, et al. "Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects." Cancer Chemother Pharmacol 53 (2004): 102-6. [PMID: 14605865]
128 Product Information. Nuvigil (armodafinil). Cephalon Inc, West Chester, PA.
129 Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
130 James WA, Lippmann S "Bupropion: overview and prescribing guidelines in depression." South Med J 84 (1991): 222-4. [PMID: 1899294]
131 Paolini A, D'Incalci M "Effect of phenobarbital pretreatment on the metabolism and antitumor activity of hexamethylmelamine." Cancer Treat Rep 70 (1986): 513-6. [PMID: 3084083]
132 Hansen BS, Dam M, Brandt J, et al "Influence of dextropropoxyphene on steady state serum levels and protein binding of three anti-epileptic drugs in man." Acta Neurol Scand 61 (1980): 357-67. [PMID: 6998251]
133 Product Information. Apadaz (acetaminophen-benzhydrocodone). KemPharm, Inc, Coralville, IA.
134 Sekar M, Mimpriss TJ "Buprenorphine, benzodiazepines and prolonged respiratory depression." Anaesthesia 42 (1987): 567-8. [PMID: 3592200]
135 Bock KW, Wiltfang J, Blume R, Ullrich D, Bircher J "Paracetamol as a test drug to determine glucuronide formation in man: effects of inducers and of smoking." Eur J Clin Pharmacol 31 (1987): 677-83. [PMID: 3556375]
136 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
137 Neuvonen PJ, Penttila O "Interaction between doxycycline and barbiturates." Br Med J 1 (1974): 535-6. [PMID: 4817187]
138 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
139 Product Information. Aczone (dapsone topical). QLT USA, Inc, Fort Collins, CO.
140 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
141 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
142 Product Information. Xtandi (enzalutamide). Astellas Pharma US, Inc, Deerfield, IL.
143 Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
144 Product Information. Otezla (apremilast). Celgene Corporation, Summit, NJ.
145 Product Information. Adempas (riociguat). Bayer Pharmaceutical Inc, West Haven, CT.
146 Pithavala YK, Tortorici M, Toh M, et al "Effect of rifampin on the pharmacokinetics of axitinib (AG-013736) in Japanese and Caucasian healthy volunteers." Cancer Chemother Pharmacol 65 (2010): 563-70. [PMID: 19603168]
147 Helleberg L, Rubin A, Wolen RL, et al "A pharmacokinetic interaction in man between phenobarbitone and fenoprofen, a new anti-inflammatory agent." Br J Clin Pharmacol 1 (1974): 371-4. [PMID: 22454912]
148 Product Information. Abilify (aripiprazole). Bristol-Myers Squibb, Princeton, NJ.
149 Product Information. Stendra (avanafil). Vivus Inc, Mountain View, CA.
150 Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.
151 Aronson JK, Grahame-Smith DG "Clinical pharmacology: adverse drug interactions." Br Med J 282 (1981): 288-91. [PMID: 6779990]
152 Jamis-Dow CA, Klecker RW, Katki AG, Collins JM "Metabolism of Taxol by human liver microsomes and effect of inhibitors (Meeting abstract)." Proc Annu Meet Am Assoc Cancer Res 34 (1993): a21981993.
153 Aggeler PM, O'Reilly RA "Effect of heptabarbital on the response to bishydroxycoumarin in man." J Lab Clin Med 74 (1969): 229-38. [PMID: 4184022]
154 Product Information. Eliquis (apixaban). Bristol-Myers Squibb Canada Inc, Montreal, IN.
155 Product Information. Zanaflex (tizanidine). Acorda Therapeutics, Hawthorne, NY.
156 Product Information. Onglyza (saxagliptin). Bristol-Myers Squibb, Princeton, NJ.
157 Product Information. Tradjenta (linagliptin). Boehringer Ingelheim, Ridgefield, CT.
158 Product Information. Orilissa (elagolix). AbbVie US LLC, North Chicago, IL.
159 Product Information. Zyrtec (cetirizine). Pfizer US Pharmaceuticals, New York, NY.
160 Kapil RP, Axelson JE, Mansfield IL, et al. "Disopyramide pharmacokinetics and metabolism: effect of inducers." Br J Clin Pharmacol 24 (1987): 781-91. [PMID: 3440098]
161 Sams RA, Muir WW. Effects of phenobarbital on thiopental pharmacokinetics in greyhounds. Am J Vet Res. 1988;49(2):245-249. [PMID: 3348533]